How do you mix thymosin alpha-1?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds Thymosin Alpha-1 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
The Zadaxin label copy on RxList mixes a 1.6 mg vial with 1 mL of sterile water (1.6 mg/mL) and, for chronic hepatitis B as monotherapy or in combination with interferon, gives 1.6 mg subcutaneously twice a week for 6 to 12 months, or 40 µg/kg for patients weighing less than 40 kg.1
The guide's example
1,600 mcg of Thymosin Alpha-1 from a 1.6 mg vial mixed with 1 mL is 100 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water |
|---|---|
| 1.6 mg | 1.6 mg/mL: 1,600 mcg is 100 units |
Vial, water and syringe marks
The Zadaxin label copy says it is supplied in single use vials of 1.6 mg of lyophilized thymosin alpha 1, two vials to a carton with two 1.0 mL ampoules of Sterile Water for Injection.1 It says to reconstitute with the 1 mL of supplied water immediately before use, for subcutaneous and not intravenous injection.1 The ETASS trial in severe sepsis (361 patients) reconstituted its powder in 1 mL of sterile water, giving 1.6 mg/mL.2
FDA's briefing lists Zadaxin at 1.6 mg/mL when reconstituted and Timosina at 2 mg/mL.3 It also names a nominated 3 mg/mL injection for subcutaneous use.3 No saved source gives another vial strength, or another water volume for the Zadaxin vial.
Worked example: the label copy's 1.6 mg dose (1600 mcg) from a 1.6 mg vial mixed with 1 mL (1.6 mg/mL) is 1 mL;1 on a U-100 syringe that is 100 units by arithmetic, as no saved source gives a syringe mark.
1,600 mcg of Thymosin Alpha-1 from a 1.6 mg vial mixed with 1 mL is 100 units on a U-100 syringe.
Doses and schedules in the label and trials
FDA's briefing says 1.6 mg subcutaneously was the dose used in most clinical studies.3 It describes an Italian authorisation of Zadaxin as a 1.6 mg powder, as an adjuvant to influenza vaccination in immunocompromised individuals: one vial, IM or SC, twice weekly for four weeks from the first vaccination, repeated from the eighth week up to the twelfth week.3
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| TESTS (Wu and colleagues, 2025)45 | 1.6 mg subcutaneously every 12±2 hours, against placebo | 1106 adults aged 18-85 years with sepsis (552 thymosin α1, 554 placebo) | Not more than 7 days, depending on the change of the subjects' condition |
| ETASS2 | 1.6 mg Tα1 subcutaneously, twice per day then once per day, against control | 361 patients with severe sepsis (181 Tα1, 180 control) | Five days twice a day, then two days once a day |
| Kim, 20126 | 1.6 mg of thymosin α-1 twice a week (route not stated), with 180 μg of peginterferon α-2a weekly, against peginterferon alone | Fifty-one patients with HBeAg-positive chronic hepatitis B (26 combination, 25 alone) | Thymosin α-1 for first 12 weeks of 48 |
| Lee, 20087 | 1.6 mg subcutaneously, twice a week, with lamivudine (100 mg orally, daily), against lamivudine alone | Sixty-seven patients with HBeAg-positive chronic hepatitis B (34 combination, 33 alone) | 24 weeks, then lamivudine continued |
Four hundred eighty-eight patients with metastatic melanoma (Maio and colleagues, 2010) were randomly assigned to five groups: Talpha1 at 1.6 mg, 3.2 mg or 6.4 mg with dacarbazine and interferon alfa, Talpha1 3.2 mg with dacarbazine, or dacarbazine and interferon alfa alone; the source gives no schedule or route, and patients were observed for up to 24 months.8 The registered phase 1 trial NCT06821100, an open label study in adults aged 65 to 100 years receiving a COVID-19 booster, lists 4.8 mg of Ta1 (1.6 mg in 1 mL of diluent, three times) on Day 0, or on Day 0 and Day 3, against no Ta1; the registry gives no route.9 The TESTS authors give 1.6 mg twice weekly as the conventional dose in cancers and viral hepatitis, and cite a previous sepsis study in which 3.2 mg daily for one week with anti-inflammatory drugs reduced morbidity and mortality, whereas 1.6 mg daily was ineffective.4
Storage of the vial and the mixed dose
The Zadaxin label copy says to store the vial between 2° and 8°C and to use reconstituted product immediately.1 The saved sources give no stability data for the reconstituted Zadaxin vial beyond that wording. FDA's briefing gives other figures for the bulk substance: it reports that lyophilized Ta1 free base is stable at room temperature for three weeks, but that storage desiccated below -18°C is recommended.3
Frequently asked questions
Do you cycle thymosin alpha-1?
Is thymosin alpha-1 approved in the US?
FDA's briefing says neither Ta1 (free base) nor its acetate form is a component of an FDA-approved drug.3
What did FDA say about compounding thymosin alpha-1?
At its advisory committee meeting, FDA proposed that thymosin alpha-1 free base, and likewise the acetate, not be included on the 503A bulks list.10 FDA's briefing document also notes that the doses and routes are inconsistent across the studies, and that the Ta1-related substance tested in most studies is unclear.3
References
- RxList. Zadaxin (Thymalfasin): Side Effects, Uses, Dosage, Interactions, Warnings. rxlist.com
- Journal. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. 2013. pmc.ncbi.nlm.nih.gov
- FDA. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. fda.gov
- Journal. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. 2025. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT02867267: The Efficacy and Safety of Ta1 for Sepsis. 2021. clinicaltrials.gov
- PubMed. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. 2012. pubmed.ncbi.nlm.nih.gov
- PubMed. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. 2008. pubmed.ncbi.nlm.nih.gov
- PubMed. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. 2010. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT06821100: Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine. 2026. clinicaltrials.gov
- FDA. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. fda.gov